Pancreatic Cancer Research

ResearcherUniversity of AntwerpActive in the last 2 years

Jonas R.M. Van Audenaerde

Matched on ORCID iD 0000-0002-5619-1913; OpenAlex author ID A5026684098. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
16
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Protein-level profiling of TIGIT axis components in human PDAC reveals immune-suppressive expression patterns. Last author DOI 10.1007/s00262-026-04343-w↗
  2. IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting. Last author DOI 10.1016/j.omton.2026.201316↗
  3. Capturing the Heterogeneity of the PDAC Tumor Microenvironment: Novel Triple Co-Culture Spheroids for Drug Screening and Angiogenic Evaluation. Co-author DOI 10.3390/cells14060450↗
  4. Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pharmthera.2022.108107↗
  5. Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. Co-author DOI 10.3390/cancers13050987↗
  6. Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. Co-author DOI 10.1002/cti2.1165↗
  7. Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers11101597↗
  8. Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.pharmthera.2018.04.003↗
  9. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Co-author DOI 10.18632/oncotarget.18185↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Geert Roeyen · 8 shared papers, 2017–2026 · strength 1.20
  2. Evelien Smits · 8 shared papers, 2017–2026 · strength 1.04
  3. Marc Peeters · 7 shared papers, 2017–2026 · strength 0.83
  4. Delphine Quatannens · 5 shared papers, 2020–2026 · strength 0.83
  5. Hans Prenen · 4 shared papers, 2021–2026 · strength 0.72
  6. Christophe Deben · 4 shared papers, 2019–2026 · strength 0.64
  7. Annemie Bogaerts · 2 shared papers, 2019–2025 · strength 0.31
  8. Jinthe Van Loenhout · 3 shared papers, 2017–2020 · strength 0.23
  9. Ruben Verloy · 1 shared paper, 2025 · strength 0.23
  10. Angela Privat‐Maldonado · 1 shared paper, 2025 · strength 0.23
  11. Laura Gehrcken · 1 shared paper, 2026 · strength 0.22
  12. Sara R. Zanivan · 1 shared paper, 2021 · strength 0.11
  13. Andreas Domen · 1 shared paper, 2021 · strength 0.11
  14. Timon Vandamme · 1 shared paper, 2021 · strength 0.11
  15. Clare Y. Slaney · 1 shared paper, 2020 · strength 0.09
  16. Atsushi Masamune · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.